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PATHOPHYSIOLOGY, CLINICAL FEATURES, AND MANAGEMENT 
OF CHILDREN WITH CHRONIC LIVER DISEASES 
 
Introduction. 
Modern hepatology has only taken off in the last 50 years. Developments have depended 
not only on specialist hepatologists, but on developments in other related disciplines of 
medicine such as virology, immunology, biochemistry, and now, molecular medicine. A 
huge literature is available describing liver disease in adults, but pediatrics has lagged 
behind. 
Nevertheless, pediatric liver disease represent a significant cause of morbidity and 
mortality worldwide. 
The etiology of liver disease in childhood is wide and varies significantly from the adult 
population encompassing structural, genetic, infectious, metabolic, iatrogenic, and 
unknown causes; in addition, differently from adults, signs and symptoms of liver disease 
in pediatric population are often non specific and can vary greatly from child to child 
among the different liver diseases, providing challenges to the primary care provider. 
More recent advances in diagnosis and treatment, particularly the successful development 
of transplantation, have dramatically improved the outcome for infants and children with 
liver disease, so that many can now expect to grow into adult life. The gratifying survival 
of increasing numbers of young people with liver disease into adult life means that it is 
essential for adult practitioners to be cognizant of pediatric liver disease. 
Unfortunately, the investigation and management of significant pediatric liver disease 
rightly remains within the remit of specialist or transplant units. 
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To date, the same multidisciplinary approach that provided so many advances in clinical 
and research aspects of adult hepatology is still lacking in the pediatric experience, so 
recognition of pathogenesis of specific pediatric liver diseases, implications of new 
therapies, characterization of new pathological entities is still delayed by necessity for 
multidisciplinary working. 
Therefore, our research starts from the assumption that only knowledge of unexplored 
aspects can be an important tool for advancing into the management of hepatic disorders 
in children. It should be a contribute to both provide a framework to understand 
pathophisiology of some hepatobiliary disorders and offer analyses of their clinical-
laboratory manifestations and the strategies for managing them. This project might be 
also useful to create specific competences related to a integrated and multidisciplinary 
approach, as required in pediatric liver disease. Our study concerns four areas that still 
present several either pathogenetic or diagnostic uncertainties, focusing on the following 
aspects: 
 
1.  Role of cellular immunity in the pathogenesis of Biliary Atresia. 
- In Biliary Atresia inflammatory obstruction of the extrahepatic bile ducts is 
accompanied by a characteristic intrahepatic mixed cellular infiltrate composed of 
lymphocytes, macrophages, and eosinophils; do cellular immune mechanisms play a role 
in pathogenesis of Biliary Atresia? If so, how effector and regulatory Tcells are 
distributed in the liver tissue and bile duct remnant of children with Biliary Atresia? 
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2. New clinical and therapeutic aspects in pediatric autoimmune liver disease. 
- Immunoglobulin G subclass 4 (IgG4)-related liver disease is well described in adults 
and is associated with multisystemic symptoms and a particularly good response to 
corticosteroid treatment. prevalence and clinical significance of raised IgG4 levels in 
children with autoimmune are still unknown. 
- Cyclosporin has been shown to allow recovery from liver failure and to induce and 
safely maintain remission in children with autoimmune liver disease, but is usually used 
as a bridge to conventional treatment and its long-term safety and efficacy are unknown 
in pediatric patients.  
 
3. Pediatric liver transplant: immunological features and complication of calcineurin 
inhibitors treatment. 
- Transplant immunological response is a balance between the alloimmune effectors T 
cells and the immunological tolerance; calcineurin inhibitors may represent a barrier to 
immune tolerance in organ transplantation by decreasing the percentage of Treg in the 
peripheral blood in liver transplant recipients. However contradictory results have been 
reported. Indeed there are same evidence indicating that tacrolimus promotes in vitro 
expansion of Treg cells expecially in humans. To better understand the effect of 
tacrolimus in maintaining of immune tolerance versus donor alloantigens, we evaluated 
the immunephenotype and the amount of Treg cells in tacrolimus treated patients.  
- PTLD is a severe complication of transplantation linked in most cases to EBV infection. 
Prevalence in pediatric liver transplant recipients is 5-7%, mortality over 50%. PTLD is 
often recognized at the stage of lymphoma; in order to early detect PTLDs in liver 
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transplanted children, presenting with mild symptoms we evaluate adenotonsillar 
histology, obtained with a mini-invasive technique, as “sentinel tissue”. 
 
4. Broadening the spectrum of UDCA indications. 
Ursodeoxycholic acid is increasingly used for the treatment of cholestatic liver diseases 
but  experimental evidence suggests several mechanisms of action other than stimulation 
of hepatobiliary secretion, such as cytoprotective, antiapoptotic, antioxidative, 
immunomodulatory, and altering cell-signaling properties. We report the first case of a 
patient with primary NRHL associated with portal hypertension in whom UDCA therapy 
was followed by a prompt reduction and sustained normalization of liver enzymes and no 
progression of portal hypertension throughout 30 months of follow-up. 
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Chapter 1. Role of cellular immunity in the pathogenesis of Biliary Atresia. 
 
1.2. Immunohistochemical characterization of T-cells in the liver and bile duct 
remnant of children affected by Biliary Atresia. 
 
Introduction. 
Biliary Atresia (BA) is an enigmatic cause of neonatal cholestasis, occurring in 1 in 8,000 
to 1 in 18,000 live births and presenting typically within the first months of life with 
jaundice, acholic stools, and hepatomegaly in an otherwise apparently healthy infant (1). 
Inflammatory obstruction of the extrahepatic bile ducts is accompanied by a characteristic 
intrahepatic portal lesion. If diagnosed in the first 2–3 mo of life, hepatic 
portoenterostomy can restore bile flow from the liver into the intestinal tract in 30 – 80% 
of patients (1–3). Despite successful surgery, progressive inflammation and fibrosis of 
intrahepatic bile ducts develops to varying degrees in all patients, leading to biliary 
cirrhosis in the majority of patients. Consequently, 70 – 80% of BA patients will 
eventually require liver transplantation, approximately half in the first 2 y of life (4 – 6). 
Thus, BA is the most common indication for liver transplantation in children, responsible 
for almost 50% of all pediatric liver transplants. It should be emphasized that it is the 
intrahepatic biliary lesion that determines overall prognosis and outcome, thus, this 
disease is no longer called “extrahepatic” BA. Without a better understanding of the 
etiology and pathogenesis of this intrahepatic sclerosing cholangitic process in BA, little 
progress can be expected in improving the nontransplantation outcome of patients. 
Therefore, there has been a renewed interest in recent years in understanding the 
underlying pathogenetic mechanisms of BA. It is now apparent that BA is a phenotype 
resulting from several pathogenic processes that culminate in obstruction of the biliary 
tree (1,7). 
Cellular immune mechanisms are central to the pathogenesis of experimental BA. 
(ABSTR) Biliary innate immunity is involved in the pathogenesis of cholangiopathies in 
patients with with primary biliary cirrhosis (PBC) and BA. Biliary epithelial cells possess 
an innate immune system consisting of the Toll-like receptor (TLR) family and recognize 
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pathogen-associated molecular patterns (PAMPs). Tolerance to bacterial PAMPs such as 
lipopolysaccharides is also important to maintain homeostasis in the biliary tree. In PBC, 
CD4-positive Th17 cells characterized by the secretion of IL-17 are implicated in the 
chronic inflammation of bile ducts and the presence of Th17 cells around bile ducts is 
causally associated with the biliary innate immune responses to PAMPs (8). 
At the time of diagnosis of BA, the extrahepatic duct remnant is composed of fibrous 
tissue and scattered lymphocytes (9) whereas intrahepatic ducts are surrounded by a 
mixed cellular infiltrate composed of lymphocytes, macrophages, and eosinophils (36; 
10). The role of the immune system in bile duct injury and obstruction is poorly 
understood at present and is the focus of intense investigation.  
 
Aim 
To characterize immunohistochemically effector and regulatory Tcells in the liver tissue 
and bile duct remnant of children with BA, to investigate for the first time the presence of 
Th17 cells in liver and biliary remnants of BA patients.  
 
 
Patients and Methods. 
Archived paired percutaneous liver biopsies (LB) and biliary remnants (BR) from 7 
children with BA were studied. Bile duct tissue from 6 children with choledochal cyst 
(CC) were also evaluated as control. Avidin-Biotin immunoperoxidase technique was 
used to investigate the following lineage-specific markers: transcription factor T-bet 
(Th1), GATA-3 (Th2), FOXP3 (regulatory T cells, Tregs) and IL-17 (Th17).  
Breifly, antigen was demasked by placing the biopsies in plastic jar containing citrate 
buffer saline (pH: 6.1) and micro waved at 600 W (2 x 5minutes).  After cooling for 15 to 
30 minutes, biopsies were washed and placed in phosphate-buffered saline for 5 minutes. 
Endogoenous peroxidase was neutralized using Peroxidase Block for 30 minutes, then 
washed and placed in PBS for 5 minutes. Non-specific background staining was inhibited 
by 10 minutes incubation of the biopsies with 10 % horse serum. (Vector Laboratories)  
After washing avidin -biotin blocking reagent was applied for 30 min to block 
endogenous biotin. After washing the sections were then incubated with a polyclonal goat 
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anti-human IL-17 antibody for one hour at room temperature. Here we used three 
dilutions of goat anti-human IL-17 antibody at 1/10,1/30,1/100 in PBS. Optimal dilution 
of the primary antibodies used in this detecting system was defined to give a specific 
staining with no or minimal background. After washing, the sections were then incubated 
with biotin conjugated secondary antibody anti-goat (Horse anti-goat IgG, Vector 
Laboratories, diluted 1/50) for 30 minutes. Immune reactivity was visualized by avidin-
biotin- peroxidase complex (ABC complex, Vector Laboratories) kit reagents. Peroxidase 
activity was developed by using  mixture of DAB substrate solution (as mentioned 
above) for 8 minutes then washed and placed in  PBS. Finally biopsies were 
counterstained with hematoxylin and prepared for microscopic examination by placing a 
cover slip on the liver biopsies on the slide. All tissues used were also tested as negative 
controls (omitting the primary antibody) with each detection to detect background or any 
false positivity caused by the detection system. 
A semi-quantitative scoring system (0 to 3+) was used for evaluation of results.  
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Results. 
Main results of our study are summarized in Table. 
 
Table. Immunohistochemical characterisation of T-cells in 7 children affected by BA (Pt) 
and in 6 children affected by CC (Control). 
 
Biliary atresia T-bet GATA-3 FOXP3   IL-17 
PT 1 LB 
         BR 
++ 
+ 
+/- 
neg 
+++ 
neg 
+++ 
+++ 
PT 2 LB 
         BR 
++ 
++ 
neg 
neg 
+ 
neg 
+++ 
++ 
PT 3 LB 
         BR 
++ 
neg 
neg 
neg 
+++ 
+ 
+++ 
+ 
PT 4 LB 
         BR 
+++ 
+ 
neg 
neg 
+ 
neg 
+++ 
++ 
PT 5 LB 
         BR 
+++ 
neg 
neg 
neg 
+ 
neg 
++ 
+ 
PT 6 LB 
         BR 
+++ 
+++ 
neg 
neg 
neg 
neg 
+++ 
++ 
PT 7 LB 
         BR 
++ 
neg 
neg 
neg 
neg 
neg 
++ 
++ 
Choledocal 
    
Control 1 + neg + ++ 
Control 2 neg neg neg ++ 
Control 3 + neg neg + 
Control 4 neg neg + ++ 
Control 5 neg neg neg Neg 
Control 6 neg neg neg Neg 
 
LB = liver biopsy; BR = biliary remnants 
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In BA, Th1 and Th17 effector cells are abundant, with a particularly high frequency of 
Th17 cells in both liver tissue and bile duct remnant (Figure 1). Th2 cells are negligible 
and none of our patients showed clear immunohistochemical positivity for GATA-3; also 
all choledocal cyst controls were negative for GATA-3. 
Tregs are variably represented, being particularly abundant in the liver biopsies of 
patients 1 and 3. 
Both Th1 and Th17 cells are well represented both in LB and BR, but in 5/7 patients it is 
present a greater positivity in LB than in BR that could be explained by the presence of 
more abundant fibrotic tissue in BR samples. In CC, all cell lineages are markedly less 
represented than in BA apart from Th17 (Figure 3) that is present in 4 patients, though 
less abundantly than in BA. 
 
Discussion. 
T-cell activation requires the interaction of the T cell with an APC-bearing antigen in the 
context of MHC class I (for cytotoxic CD8+ T cells) or MHC class II (for helper CD4+ T 
cells). In the inflammatory environment, naïve CD4+ T cells differentiate to either Th1 
effector cells (driven by IL-12 and producing IFN-γ, IL-2, TNF-β, and TNF-α) or Th2 
effector cells (driven by IL-4 and producing IL-4, IL-5, and IL-10).  
Previous studies showed that in BA patients, T-cell infiltrates surround and invade 
intrahepatic bile ducts (11); this infiltrates are characterized predominantly by CD4+ T 
cells (12-14), CD8+ T cells (15), or a mixture of both (16). Activated effector T cells 
produce cytokines that can directly damage epithelial cells or indirectly damage them 
through stimulation of other immune cells. 
Recent investigation has revealed that BA is associated with Th1-cell-mediated portal 
tract inflammation. Mack CL et al. have shown that the periductular immune cells in BA 
produce IL-12, IFN-γ, IL-2, and TNF-α ; in their study this localized inflammatory profile 
was unique to BA and was not found in other neonatal cholestatic diseases (16). Bezerra 
et al. (17 44) used gene expression microarray techniques to analyze BA liver biopsies 
and observed up-regulation of a number of pro-inflammatory genes (including the Th1 
cytokines IFN-γ and osteopontin) and down-regulation of Ig genes suggesting inhibition 
of Th2 pathway.  
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Confirming these previous results, our study showed a considerable presence of Th1 cells 
infiltration both in liver parenchyma and in biliary remnants of children affected by BA 
and the absence of Th2 cells. 
However, main result of our study was to demonstrate for the first time in literature the 
presence of an abundant infiltrate of Th17 cells in BA patients; specifically our data show 
that Th17 is the most prevalent type of effector T-cell in BA, a condition hitherto 
considered to be mainly Th1 induced. 
It is known that the recently discovered Th17 cells characterized by the secretion of IL-17 
have a pro-inflammatory property. Specifically, it has been reported that Th17 and Treg 
have reciprocal developmental pathways (18). 
A fine balance between Th17 and Treg may be crucial for the stability of immune 
homeostasis. Once the equilibrium is broken, the destabilization may lead to chronic 
inflammation and autoimmunity. 
Intriguingly, it has been demonstrated that murine helper T cell (Th) differentiates 
towards Th17 and Treg in a mutually exclusive manner (18). 
Overall, in our study Tregs cells were consistently less represented than Th17 cells and 
this finding was specifically evident in biliary remnants where, at time of sampling, the 
inflammatory damage was more advanced than in liver parenchyma.  
Nevertheless, how cells of the Th17 lineage may be involved in pathogenesis of BA 
remain still unknown and further investigations are needed to clarify the role of these 
cellular immunity effectors in bile duct damage. 
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Figure 1. 
Th17 positivity in liver tissue (A) and biliary remnants (B) in Pt 1Th17 positivity in liver 
tissue (A) and biliary remnants (B) in Pt 1
A
B 
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Figure 2. 
Th1 positivity in liver tissue (A) and biliary remnants (B) in Pt 6Th1 positivity in liver 
tissue (A) and biliary remnants (B) in Pt 6 
A
B 
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Figure 2. 
Th17 positivity in Control 1 at different magnifications.  
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Chapter 2. New clinical and therapeutic aspects in pediatric autoimmune liver 
diseases. 
 
2.1 Prevalence and significance of raised IgG4 in paediatric autoimmune liver disease: 
a retrospective study. 
 
Introduction. 
Autoimmune hepatitis (AIH) is an organ-specific autoimmune disease characterized by 
chronic inflammation of the liver, elevated transaminase levels, 
hypergammaglobulinemia, serum autoantibodies, histological evidence of interface 
hepatitis, and a favorable response to immunosuppressive treatment (1-3). A working 
model for its pathogenesis postulates that environmental triggers, a failure of immune 
tolerance mechanisms, and a genetic predisposition collaborate to induce a T cell–
mediated immune attack upon liver antigens, leading to a progressive necroinflammatory 
and fibrotic process in the liver (4,5). The diagnosis is based on histologic abnormalities, 
characteristic clinical and laboratory findings, abnormal levels of serum globulins, and 
the presence of one or more characteristic autoantibodies (6 -10). 
IgG4 is a minor component of the four subclasses of IgG in serum; little attention has 
been paid to this minor component of IgG since Hamano et al. found elevated serum 
IgG4 level in patients with autoimmune pancreatitis (AIP) (11). 
Thereafter, many studies of AIP were reported, mainly by Japanese investigators. The 
histopathological findings of AIP are characterized by the periductal localization of 
predominantly CD4-positive T cells, IgG4-positive plasma cells, storiform fibrosis with 
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acinar cell atrophy frequently resulting in stenosis of the main pancreatic duct, and 
obliterative fibrosis (12-14), which is also called lymphoplasmacytic sclerosing 
pancreatitis (LPSP) (15). In 2003, Kamisawa et al. (16) suggested that AIP is a systemic 
sclerosing disease, based on the findings that the pancreas and other involved organs have 
fibrosis with abundant infiltration of IgG4-positive plasma cells, which is similar to the 
concept of multifocal fibrosclerosis proposed by Comings et al. (17) a systemic disease 
characterized by extensive IgG4-positive plasma cell and T lymphocyte infiltration of 
various organs. Clinical manifestations are apparent in organs such as the pancreas, bile 
duct, gallbladder, salivary gland, retroperitoneum, and others where tissue fibrosis with 
obliterative phlebitis is present on pathology.  
Immunoglobulin G subclass 4-associated cholangitis (IAC) is a biliary disease of 
unknown immunopathogenesis, with cholangiographic features indistinguishable from 
PSC, but distinct histological findings and a dramatic response to corticosteroids (18). In 
the largest cohort of 53 IAC patients from the Mayo clinic, median age at diagnosis was 
60 years in a predominantly male-patient group (85%), frequently presenting with 
obstructive jaundice (19). IBD is less frequently associated with IAC than PSC, described 
predominantly in case reports and small series, although IgG4 positive plasma cells have 
been detected in colonic specimens in patients with autoimmune pancreatitis and IgG4-
related colitis may mimic IBD (20,21). Diagnostic criteria have been proposed for IAC 
based on characteristic histological and cholangiographic findings, elevations in serum 
IgG4, systemic organ involvement and response to corticosteroids (19). These are still to 
be cross-validated in an independent cohort of patients. 
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Recently, Umemura T et al. reported a case suggesting the existence of a new disease 
entity termed ‘‘immunoglobulin G4 (IgG4)-associated AIH’’; although the revised 
IAIHG disease score of this patient was 18 and representative of definite AIH, a high 
serum IgG4 concentration was detected before the administration of corticosteroid 
therapy. Moreover, immunostaining of liver tissues prior to treatment showed abundant 
plasma cells with strong immunohistochemical reactivity to IgG4 (22). 
Immunoglobulin G subclass 4 (IgG4)-related liver disease is well described in adults and 
is associated with multisystemic symptoms and a particularly good response to 
corticosteroid treatment. The significance of raised serum IgG4 in paediatric liver disease 
is unclear. 
 
Aim. 
Aim of present study was to investigated prevalence and clinical significance of raised 
IgG4 levels in a large cohort of children with autoimmune liver disease. 
 
Methods. 
Retrospective review of medical records, clinical, biochemical, radiological and 
histological data of 75 children with autoimmune liver disease (42 autoimmune hepatitis 
[AIH] and 33 autoimmune sclerosing cholangitis [ASC]) diagnosed from 2005–08. IgG4 
levels were tested retrospectively in stored serum (-80°C) collected at or close to 
diagnosis by immunoenzymatic assay (ELISA). Levels >1.35 g/L were considered 
abnormal, based on published data in autoimmune pancreatitis. Patients were divided into 
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two groups: Group 1 (high IgG4) and Group 2 (normal IgG4). In 63 children with 
available liver biopsy at presentation, histological activity, staging, and number of IgG4þ 
plasma cells per high power field were also investigated. 
 
Results. 
Group 1 comprised 25 children (33%), 12 with AIH and 13 with ASC; group 2 comprised 
50 children, 30 with AIH and 20 with ASC. Inflammatory bowel disease was diagnosed 
in 28% of both groups. Group 1 had significantly higher IgG levels (median 29.4 g/L, 
range 14.5–63.8, P<0.001) and IgG4/IgG ratio (9.9 [2.3–27.7], P<0.001) compared to 
Group 2. Within patients with AIH, those in Group 1 had lower C3 levels (0.86 g/L, 
[0.41–1.35] P=0.019) than those in Group 2. There was no difference in liver function 
tests and histological activity/staging at presentation between the 2 groups. IgG4+ cells 
(≥ 5 cells) within the liver tissue were more commonly seen in Group 1 than Group 2 
(27% vs. 2%), but ≥10 IgG4 positive cells, as described in adult IgG4-related disease, 
were not identified. Granulocyte epithelial lesions were seen in only one case of ASC 
within Group 2. After a median follow up of 3 years [2–5] normal AST, 
immunoglobulins and negative auto-antibodies were recorded in 62% in Group 1 and 
51% in Group 2. 
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Conclusion. 
Thirty-three percent of children with autoimmune liver disease evaluated in our study 
have high IgG4 levels at diagnosis with no difference between AIH and ASC. This 
proportion is higher than that reported in adults with AIH (3%) or primary sclerosing 
cholangitis (9%). No difference in disease severity or response to treatment was observed 
medium-term between patients with low or high IgG4, but longer follow up is necessary 
to determine whether children with high IgG4 represent a specific subtype of paediatric 
autoimmune liver disease. 
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2.2 Steroid Responsive Autoimmune Sclerosing Cholangitis with Liver Granulocytic 
Epithelial Lesions. 
 
Introduction. 
During a retrospective review to determine the long-term outcome of patients with 
autoimmune liver disease referred to our tertiary Centre, we identified a boy with 
autoimmune sclerosing cholangitis (ASC), inflammatory bowel disease (IBD), and a 
dramatic response to steroid treatment, whose original liver biopsy showed granulocytic 
epithelial lesions identical to those described in autoimmune pancreatitis type 2. 
 
Case report 
A 13-year-old boy was referred to our Centre in March 1985 with a 5-month history of 
abdominal pain, bloody diarrhoea, abnormal liver function tests (LFTs) and weight loss. 
Positive findings were splenomegaly, leg and buttock erythema nodosum and pruritus. 
Paternal grandmother had rheumatoid arthritis and maternal grandmother Reynaud’s 
syndrome and ankylosing spondylitis. 
In December 1984, admitted locally with pyrexia and abdominal pain, he had abnormal 
LFTs, raised white cell count and erythrocyte sedimentation rate. A month later, a barium 
follow-through suggested Crohn’s disease, prompting referral to a gastroenterology unit, 
where abdominal ultrasound (US) showed diffuse liver parenchymal changes and 
moderate splenomegaly. An endoscopic retrograde cholangiopancreatography (ERCP) 
demonstrated normal pancreatogram, but intrahepatic cholangiopathy. Aspartate 
aminotransferase (AST) levels were 6-10 times the upper limit of normal (ULN), gamma 
glutamyltransferase (GGT) levels 5 times/ULN, alkaline phosphatase (ALP) levels at 
ULN for age. An exploratory laparotomy to exclude tuberculosis or lymphoma, was 
negative. A wedge liver biopsy showed active cholangitis. He was treated with 
salazapyrin 2g/day, with improvement of bowel symptoms, and was referred to our 
Centre for further evaluation/management. 
On admission, AST was 180 IU/l, ALP 160 IU/l (n.v. <200IU/l), GGT 87 IU/l, 
immunoglobulin G (IgG) 20.9g/l (n.v. 7-18.6g/l), serum amylase 270 IU/L (n.v. <100 
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IU/L), antinuclear antibody positive (1/160). Serum IgG4, tested retrospectively in a 
sample stored at -80oC from his first admission, were 0.64 g/l (n.v. <1.35g/l).  
A colonic biopsy demonstrated active colitis. Review of the liver wedge biopsy 
performed in the referring hospital showed slightly distorted lobular architecture with 
periportal fibrosis (Fig. 1A); enlarged portal tracts with moderate lymphocyte and plasma 
cell infiltrate and interface activity; inflamed bile ducts with epithelial damage and focal 
periductal concentric fibrosis (Fig. 1B). Current review of the same biopsy additionally 
reveals bile duct injury characterised by irregular epithelial configuration with 
intraepithelial neutrophilic infiltration (Fig. 1C, D), and obliterative phlebitis of portal 
vein branches (Fig. 1E).  
ASC  with IBD was diagnosed and treated with sulphasalazine 2 g/day and prednisolone 
10 mg qds for 2 weeks, gradually reduced to 5 mg od. Over six months the patient 
became asymptomatic and normalised LFTs, amylase and IgG. A year later, after a 
surveillance liver biopsy showed mild periportal fibrosis without portal inflammation or 
bile duct damage (Fig. 1F), prednisolone was decreased to 5 mg/alternate days. Two 
years later a repeat liver biopsy showed minimal non-specific changes with well 
preserved bile ducts.  
A follow-up ERCP in 1989 evidenced cholangiopathy of the second, third and fourth 
order bile ducts (Fig 2). In 1990, a further ERCP showed no progression of 
cholangiopathy.  
Between 2000 and 2008 three episodes of IBD exacerbation responded to a temporary 
increase of steroid dose and mesalazine 800 mg tds. Maintenance prednisolone was 
stopped in 2008.  
At the age of 37 he underwent cholecystectomy for symptomatic gallstones. At last 
follow-up in 2010, he had normal LFTs and no bowel symptoms while on mesalazine 
800 mg tds and ursodeoxycholic acid 500 mg bd (started in 2005).  
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Discussion  
Autoimmune pancreatitis (AIP) is an idiopathic disorder characterised by positive 
autoantibodies, association with other autoimmune pathologies and excellent response to 
steroids (1). AIP affects mostly adults, though a paediatric case is described (2), and is 
classified into type 1 (AIP-1) and type 2 (AIP-2).  
AIP-1 is the pancreatic manifestation of an IgG4-related systemic disease characterized 
by high serum IgG4, IgG4-positive plasma cell infiltration of the pancreas, proximal bile 
ducts, retroperitoneal, renal, and salivary tissue, (3). AIP-1 is associated to bile duct 
damage (5) (6). A 3-year-old girl with steroid responsive? IgG4-associated cholangitis  
(elevated serum IgG4 and hepatic infiltration with IgG4-positive plasma cells), but 
without pancreatic involvement, has been recently reported (7). 
AIP-2 has no specific serological markers, but is characterised on histology by a 
neutrophilic pancreatic duct damage known as granulocytic epithelial lesion (GEL) (4). 
Cholangiopathy is not a feature of AIP-2. A recent paediatric case report, however, 
describes a 10-year-old boy with severe abdominal pain, normal IgG4 levels, borderline 
raised serum amylase, negative autoantibodies, multiple stenosis of the pancreatic duct, 
dilatation of the bile ducts, and good response to steroids, who appears to have an AIP-2 
related cholangiopathy, though no histological description of the liver or pancreas is 
provided (2).  
The patient with ASC described in this case report is unusual because of his dramatic 
response to steroid treatment with a sustained long-term remission of liver disease, even 
on alternate day low-dose prednisolone and after complete withdrawal. Such a benign 
course is uncommon in ASC, where progressive liver damage is observed in most cases 
at medium/long-term follow-up (8).  At presentation, he had histological liver lesions 
characterised by periductal and intraepithelial neutrophilic infiltration identical to those 
described in the pancreatic duct in AIP-2. Though GEL in our patient may have been due 
to a superimposed suppurative cholangitis, the histological findings do not support this, 
since suppurative cholangitis is characterised by numerous neutrophils in the ductal 
lumen with abscess formation and attenuation or disruption of the epithelial layer, while 
our patient had predominantly periductal and intraepithelial neutrophilic infiltration with 
irregular configuration of the bile duct epithelium. Despite a mild elevation of serum 
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amylase at disease onset, he had no radiological evidence of pancreatitis. It is conceivable 
that, as raised IgG4 levels characterise a systemic disorder encompassing AIP-1, 
cholangitis, autoimmune hepatitis, salivary gland disease etc (4), GEL may be the 
common denominator of a spectrum of clinical manifestations including pancreatic 
and/or bile duct disease of variable severity. ASC with histological similarities to AIP-2 
may account for a subgroup of juvenile sclerosing cholangitis with excellent response to 
steroids and favourable long-term outcome. Whether GEL on liver histology predicts 
steroid responsiveness in children with sclerosing cholangitis should be evaluated 
prospectively.  
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Figure 1. A to E. Wedge liver biopsy specimen before steroid therapy. (A) There is 
fibrous enlargement of portal tracts. (B) Periductal concentric fibrosis with inflammatory 
cell infiltration is noted. (C and D) A bile duct shows a convoluted appearance with 
irregular epithelial configuration and intraepithelial neutrophilic infiltration. (E) 
Obliterative phlebitis with elastic fibres of an obliterated portal venule indicated by 
arrows (a, artery; BD, bile duct). (F) Needle biopsy specimen taken after 1 year on steroid 
therapy shows only mild periportal fibrosis with a few reactive bile ductules. A-D and F: 
Haematoxylin and eosin; E: Elastica van Gieson; Magnification: ×20 (A), ×100 (B, E), 
and ×200 (C, D, F). 
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Figure 2. Endoscopic retrograde cholangio pancreatography  (ERCP). There is localised 
stricturing, dilatation and irregularity of the second, third and fourth order intrahepatic 
ducts with minimal changes of the first order main left and right ducts. The extrahepatic 
common hepatic and common bile ducts are spared. 
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2.3 Autoimmune liver diseases (AILD) treatment: cyclosporin is safe and efficacious 
in the long term. 
 
Objectives and Study. 
Cyclosporin (CS) has been shown to allow recovery from liver failure and to induce and 
safely maintain remission in children with AILD. However CS is generally used as a 
bridge to conventional treatment and its long-term safety and efficacy are unknown. This 
study reviewed patient data to evaluate the long-term safety and efficacy of CS treatment 
of AILD. 
 
Methods. 
We reviewed records of 30 patients (23 females) treated with CS for more than 12 
months in the last 20 years: 22 had autoimmune hepatitis (12 type 2, 6 type 1 and 4 
seronegative) and 8 an overlap syndrome (5 with autoimmune sclerosing cholangitis, 3 
with autoimmune cholangitis). 19 of them were CS first-line treated while in 11 CS was a 
secondline option. Indications for CS as a second-line option were treatment failure 
and/or contraindications to/refusal of steroids. In 17 of the patients, CS was the only 
immunosuppressant drug administered. As for the remaining 13, CS was administered 
with azathioprine and/or prednisone in 12 cases, with prednisone and mycophenolate 
mofetil in 1. Patients with overlap syndrome also received ursodeoxycholic acid. 
Treatment was started at a median age of 116 mo. (26-253) and the median treatment 
duration was 48 mo. (12-192). 18 patients were shifted to another treatment (17) or 
withdrawn from therapy (1) after a median of 16 mo. (1-54), while 12 are currently in 
treatment with CS. 
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Results. 
The median follow-up was 4.8 yrs (1.3-18). All 19 patients first-line treated with CS 
achieved complete remission in a median period of 8 wks (3-20). 4 of them required a 
combination with conventional therapy due to severely impaired liver function. In all but 
one patient who shifted to CS after conventional treatment during a relapse, CS allowed 
maintenance of remission with minimal to no dosages of steroids. In 1 patient with 
autoimmune sclerosing cholangitis, CS was not clearly beneficial. Tolerance to CS was 
excellent. Mild to moderate hypertrichosis occurred in 11 and gingival hypertrophy in 13. 
These side effects improved after dose tapering, or disappeared at the end of treatment 
and were well tolerated. In 1 patient the occurrence of painful gingival ulcers lead to 
withdrawal of CS. No signs of renal function deterioration were recorded: none presented 
hypertension and no statistically significant changes in median glomerular filtration rate 
were observed between the beginning and the end of treatment. A transient serum 
creatinine elevation up to 55% occurred in 4 cases. In all it returned to baseline after a 
reduction of dose. 
 
Conclusion. 
CS may be considered a safe treatment and an effective alternative for front-line therapy 
in AILD. Even after prolonged treatment and long-term follow-up renal function remains 
normal, however accurate renal function monitoring is mandatory. 
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Chapter 3. Pediatric liver transplant: immunological features and complication of 
calcineurin inhibitors treatment. 
 
3.1 Tacrolimus regulates the proliferation of Regulatory T cells in liver transplant 
recipients 
 
Introduction 
Tacrolimus (TAC) is a T cell immunosuppressive drug also known as calcineurin 
inhibitor commonly used to treat transplant recipients. Tacrolimus binds to FKBP and 
acts inhibiting calcineurin .[1] The inhibition of the phosphatase calcineurin and, in 
consequence, of the transcription factor NFAT leads to reduction of the expression of 
several cytokine genes, including IL-2, which is an important growth factor for T cells, 
and this inhibits T cell activation. [2] Since T lymphocyte have a key role in the acute or 
chronic rejection in organ transplant, TAC is largely used to treat transplant recipients 
and in particular in liver transplants to prevent alloantigen reaction that affect the long 
term life span of transplant patients. It is clear that the transplant immunological response 
is a balance between the alloimmune effectors T cells and the immunological tolerance. 
Recent evidences indicate that Regulatory T cells (Treg) have crucial roles in the 
mechanism of transplantation tolerance determining the tolerance of the graft. [3] Treg 
cells are a subset of T lymphocyte that represents about 5-10% of CD4+ T cells. They 
constitutively express the high affinity IL-2 receptor (CD25) and the forkead family 
transcription factor, Foxp3. This cellular subset inhibits the activation and the 
proliferation of effectors T cells in vivo and in vitro and has a crucial role in several 
contests such as the prevention of immunoinflammatory and autoimmune diseases. [4] 
There are several data indicating that Treg cells have an important role also in controlling 
alloresponses and in induction of immunological tolerance to allografts.[5] Previous 
studies have shown that immunosuppressive therapy may have a role in tolerance control 
among liver transplant recipients. In particular calcineurin inhibitors may represent a 
barrier to immune tolerance in organ transplantation by decreasing the percentage of Treg 
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in the peripheral blood in liver transplant recipients. [6,7] However same contradictory 
results have been reported. Indeed there are same evidence indicating that TAC promotes 
in vitro expansion of Treg cells expecially in humans. [8] Despite Treg cells are anergic 
to in vitro stimulation, they are highly proliferative in vivo. [9] To better understand the 
effect of TAC in maintaining of immune tolerance versus donor alloantigens in liver 
transplant recipients, we evaluated the immunephenotype and the amount of Treg cells in 
TAC treated patients. Since the amount of Treg is correlated with the proliferative 
capacity of these cells in vivo. 
 
Aim 
To evaluate the role of TAC in the control of the in vivo proliferation of Treg cells in 
pediatric liver transplant recipients.  
 
Materials and Methods 
 
Patients 
A total of 10 stable liver transplant recipients and 13 controls were enrolled after 
informed consent. Liver transplant recipient receiving TAC based immunosuppression. 
All patients showed stable liver function. All blood samples from patients and controls 
were collected at 9.00 am in heparinised vacutainers (BD Biosciences, Milan, Italy) and 
processed within the following 3 h.  
 
Immunophenotypic Analysis 
Immunophenotypic analysis of peripheral blood from TAC treated patients and controls 
was performed with an EPICS XL flow cytometer (Beckman Coulter) using the Beckman 
Coulter software program XL system II. Triple combinations of different anti-human 
mAbs, e.g., FITC- and phycoerythrin (PE)-anti-CD3, PE- and PC-5-anti-CD4, PC5-anti-
CD8, PE-anti-CD16, PC5-anti-CD19, PE-anti-CD25, FITC-anti-CD45, and PE-anti-
CD56 (Coulter Immunotech, Marseille, France), were used for immunofluorescence 
staining. 
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Flow cytometry analysis of Foxp3 and Ki67 expression 
All cytometry analysis were performed on PBMCs isolated by Ficoll Hypaque gradient 
centrifugation from TAC treated patients and controls. The anti-human Foxp3 staining set 
was from eBiosciences (San Diego, CA). FITC-anti-human-Ki67 and PeCy5.5-anti-
human-CD4 were from BD Biosciences. 
 
Fluorescent bead-based immunoassay 
All serum samples from patients and controls were collected and stored at −80 °C before 
the analysis. Human obesity kit (Bender MedSystems GmbH, Vienna, Austria) was used 
to perform the bead based Analyte Detection Assay for quantitative detection of soluble 
MPO, ICAM-1, CD-40L, TNF-R, MCP-1, IL-6, Resistin and Leptin by Flow Cytometry. 
Preparation of the samples was performed according to manufacturer's instructions. A 96-
well plate format was used, including two eight-point standard curves (inclusive blank). 
Concentrations of analytes were proportional to fluorescent intensity measured on a BD 
FACSCanto (BD Biosciences). Data were acquired using a BD FACSCanto 
(BDBiosciences) and analysed using FlowCytomixPro 2.2 Software (Bender 
MedSystems GmbH, Vienna, Austria).  
 
Statistical analysis 
Data are presented as mean (SD). We used an unpaired t test with Welch’s correction. 
The comparisons was performed using StatView® (SAS Institute). A p value ≤0.05 was 
considered statistically significant.  
 
  
Results. 
 
Tacrolimus treated patients show a “memory” immune-phenotype 
We performed a full lymphocyte immunophenotyping of liver transplant recipients who 
did receive TAC treatment and of controls. Overall TAC treated patients showed a lower 
number of total lymphocytes, CD3+ and CD4+ cells/mm3 compared with controls. Of 
interest in TAC treated patients there was a trend toward a “memory phenotype”. Indeed 
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the absolute numbers of CD3+ CD45RA+ and  CD4+CD45RA+ cells were lower in the 
TAC treated patients (793±332 and 332±177, respectively) compared with the controls 
group (1515±831 and 843±482) (p=0.01 and 0.002). Moreover the percentage of 
CD3+CD45RO+ cells trended toward being higher in the TAC treated patients (28±7) 
compared with the controls group (18±10) (p=0.01). In agreements with these findings 
TAC treated patients had a significant lower percentage of CD4+CD45RA+ cells 
compared with controls group (17±7 vs 29±9, p=0.001). In addition patients showed a 
significant lower number of CD4+CD28+ and CD8+CD11b+ cells (595±255 and 22±16, 
respectively) compared with controls (1067±559 and 50±28). No differences were seen 
among TAC treated liver transplant recipients and controls in other cellular population 
analyzed. 
 
Tacrolimus treated patients show a lower proliferation of Regulatory T cells compared 
with controls.  
To evaluate the immunological tolerance state of TAC treated patients we analyzed the 
absolute number and the percentage of  CD4+CD25+Foxp3+ Regulatory T cells in 
peripheral blood of TAC treated patients and controls. The percentage and number of 
Regulatory T cells was decreased in TAC treated patients compared with controls. 
Human regulatory T cells are anergic to in vitro anti-CD3 and anti-CD28 stimulation but 
are high proliferative in vivo. We evaluated the in vivo proliferation of regulatory T cells 
through the evaluation of the expression of the proliferative marker ki67. We observed 
that TAC treated patients showed a lower number of proliferating Treg cells testified by 
the lower number of Ki67+ Treg cells.  
 
Tacrolimus treated patients shown an higher circulating level of sTNF-R compared with 
controls.  
To assess the role of tacrolimus in the metabolic complications of liver transplant 
recipients we measured the serum level of Leptin, sTNF-R, sICAM-1, IL-6, sCD40-L, 
Resistin, MPO and MCP-1 that represent a panel of markers involved in the mechanism 
and consequences of obesity and in maintaining of inflammatory state correlated with this 
pathology. We observed that TAC treated patients showed an higher circulating level of 
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sTNF-R compared with controls. Conversely, we did not observe any differences 
between liver transplant recipients and controls when we evaluated the others markers. 
However a more detailed analysis have shown that tacrolimus treated patients could be 
divided into two groups characterized by different levels of serum leptin. Interestingly the 
group with the higher level of leptin present a more severe clinical score.  
  
Conclusion. 
In recent years much evidence has been published on the beneficial eﬀect of Tregs in the 
induction of allotolerance. Treg cells are involved in maintaining of alloantigen immune 
tolerance through the suppression of the effectors T cells against  donor antigen. 
Immunosuppressive therapy may differently impact memory and regulatory T-cell 
subsets in liver transplant children. We analyzed the level of Tregs in liver transplant 
recipients who received TAC immunosuppressive therapy and in controls. Our data 
showed that full lymphocyte immunophenotyping of liver transplant recipients of 
tacrolimus treated patients was characterized by a lower number of total lymphocytes 
when compared with age matched controls. It is interesting to note that in tacrolimus 
treated patients there was a trend toward a “memory phenotype” even if the absolute 
numbers of CD3+ CD45RA+ and  CD4+CD45RA+ cells were lower than in controls. 
We also observed that TAC treated patients showed a lower number of proliferating Treg 
cells testified by the lower number of Ki67+ Treg cells. 
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3.2 Early detection of lymphoproliferative disorders (PTLD) in paucisymptomatic 
pediatric liver transplant recipients by adenotonsillar histology. 
Background and aims: PTLD is a severe complication of transplantation linked in most 
cases to EBV infection. Prevalence in pediatric liver transplant recipients is 5-7%, 
mortality over 50%. PTLD is often recognized at the stage of lymphoma; less aggressive 
variants are a/paucisymptomatic.  
Methods: We prospectively evaluated for PTLD all liver transplanted children with 
symptoms of nasal obstruction and/or intermittent diarrhoea and/or unexplained failure to 
thrive. Adenotonsillar tissue was obtained by rhinofibroscopy and biopsy or by 
adenotonsillectomy. 
Results: Among 120 liver transplant pediatric recipients 25 (16 males) were 
symptomatic. Median age was 4,6 years (2,5-15,6), median age at liver transplant (OLT) 
was 1,1 years (0,3-11,25), median time from OLT was 3,25 years (0,75-6,5). 5 children 
underwent adenotonsillectomy and 20 adenotonsillar biopsy. PTLD was diagnosed in 22 
(88%), in 12 identified as polymorphic, in 10 as “early lesion". Age at diagnosis or time 
from OLT weren’t significantly different between these two groups. 11 patients 
underwent gastrointestinal endoscopy. In all, PTLD involved also gastrointestinal tract. 
21/22 patients with PTLD were EBV naïve at the time of OLT. At diagnosis of PTLD 
EBV DNA on peripheral blood mononuclear cells (PBMC) was positive in 13 patients: 
median value 100/105PBMC (15-1950) but EBER RNA was detected in lymphoid tissue 
in 20. Treatment consisted in decreasing doses of tacrolimus in PTLD “early lesions”and 
in shift from tacrolimus to rapamycin in the others. After a median follow-up of 14 
months (9-60) all are alive without signs of progression to aggressive variants of PTLD. 
Conclusion: Waldeyer ring hypertrophy is associated to low grade variants of PTLD in 
liver transplanted children. EBV naïve status is a common feature. At diagnosis EBV 
DNA in PBMC is highly variable and even absent. Adenotonsillar biopsy is an easy and 
cost effective procedure to achieve diagnosis. Histological picture is consistent with 
gastrointestinal lymphoid tissue.  
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Chapter 4. Broadning the spectrum of UDCA indications. 
 
4.1 Successful Use of Ursodeoxycholic Acid in Nodular Regenerative Hyperplasia of 
the Liver 
 
Introduction. 
Nodular regenerative hyperplasia of the liver (NRHL) is a benign uncommon condition 
characterized by the diffuse transformation of normal hepatic parenchyma into 
regenerative nodules typically without fibrous septa.1 Rather than a “primitive entity”, 
nodular transformation in NRHL seems to be an aspecific adaptive response to alterations 
in blood flow secondary to a wide range of insults. Indeed, autopsy studies and case 
series have shown that the atrophic regions between nodules are associated with 
obliterative changes in the portal veins, leading to decreased blood flow in the supplied 
acini, while the nodular areas are believed to be a hypertrophic response to normal or 
slightly increased blood flow.2 NRHL is probably underdiagnosed since it is often found 
accidentally or at autopsy, and imaging studies have a poor accuracy in establishing 
diagnosis.3  
The diagnosis of NRHL is made by liver biopsy and histological criteria include the 
presence of hepatocellular nodules less than 3 mm in diameter not surrounded by fibrosis. 
1 This condition is more frequent in adults than in children 4 and in most instances is 
diagnosed in association with long-standing systemic diseases (vasculitis, collagen 
diseases, haematological or cardiovascular disorders, neoplasm and metabolic disease).1 
Some cases of NRHL have been attributed to toxic liver injury (i.e., azathioprine and 6-
thioguanine).1 NRHL is defined primary when occurs without underlying or associated 
disease. 
NRHL may remain clinically asymptomatic for many years. Common presenting features 
are abnormal liver function tests (predominantly cholestatic) and portal hypertension.1 
Since no specific treatment is available, the current management of patients with a 
primary form of NRHL consists exclusively in treating the complications of portal 
hypertension.1 In NRHL patients with associated conditions (secondary form), it is 
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unclear whether treatment of the latter affects the course of NRHL. In patients with 
NRHL and inflammatory bowel disease it has been observed that azathioprine 
withdrawal was followed by progressive normalization of liver enzymes and platelets.4 
Here we report the case of a patient with primary NRHL associated to portal hypertension 
in whom ursodeoxycholic acid (UDCA) therapy had a favourable effect on liver enzymes 
and was associated to non-progression of portal hypertension.  
 
Case report. 
A symptom-free 13-year-old boy was hospitalized for splenomegaly and 
thrombocytopenia identified during a routine check-up. Infectious, autoimmune and 
neoplastic causes were ruled out. In particular, bone marrow aspiration was 
unremarkable. The patient remained symptom-free for two years. When he was 15-year-
old, various laboratory parameters were deranged: white blood cells 1,960/mm3, platelets 
54,000/mm3, aspartate aminotransferase (AST) 67 IU/L, alanine aminotransferase (ALT) 
176 IU/L, and gamma-glutamyltransferase (GGT) 102 IU/L. Bilirubin, albumin and 
prothrombin time were in the normal range. Ultrasound scanning of the abdomen 
revealed an enlarged liver, with a sonolucent, homogeneous echopattern, and an enlarged 
spleen. The diameter of the portal vein (P) was increased (14.5 mm) and mean portal vein 
flow velocity (PVmean) was decreased (12.5 cm/sec) at ultrasonographic pulsed Doppler. 
The portal vein congestion index (CI) (cm2/[cm/sec]) was 0.132.5 Abdominal computed 
tomography showed homogeneous density of the liver, an ectasic portal vein and 
portosystemic collaterals (gastric, splenic and umbilical collaterals). The patient was 
referred to our pediatric liver unit for assessment of liver disease and related portal 
hypertension. 
On admission, the patient looked well; physical examination showed 
hepatosplenomegaly. The clinical history of the patient was reviewed for drug intake and 
parenteral exposure. Neither drugs or supplements were given within the past 6 months 
nor there was drug abuse history.  There was no history of pruritus or clinical signs of 
genetic disorders. Umbilical vein catheterization was not reported, and growth and 
neurologic development were normal. The following serological tests were performed 
and all tested negative: hepatitis A, B, C, Epstein-Barr, cytomegalovirus, HIV, 
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toxoplasmosis and Brucella. Autoimmune hepatitis and celiac disease were excluded. To 
exclude progressive familial intrahepatic cholestasis type 3, we carried out a molecular 
analysis of the MDR3 gene and the result was negative. Thyroid hormones, iron, ferritin, 
alpha-1 antitrypsin, lactate dehydrogenase, and creatine phosphokinase values were 
normal. Ceruloplasmin serum concentration was borderline (20 mg/dl) and thus we 
evaluated liver copper metabolism in detail. Basal urinary copper excretion was just 
above the upper normal limit value (43 µg/24 h), whereas post-penicillamine urinary 
copper excretion was 1165 µg/24h. Corneal Kayser-Fleisher rings were absent. Since, 
based on the patient’s Ferenci score,6 a diagnosis of Wilson’s disease was probable, we 
carried out a molecular genetic study of the ATP7B gene with negative result. Similarly, 
the most common genetic disorders with hepatic involvement, such as cystic fibrosis, 
were ruled out. Evaluation of the biliary tree structure by magnetic resonance was 
performed to exclude anatomic disorders and primary sclerosing cholangitis (PSC). The 
liver was enlarged; there were no focal lesions of liver signal intensity but only a slightly 
inhomogeneous liver structure on T1 and T2 weighted images. Magnetic resonance did 
not show any sign of PSC. Spleen size was 27 cm. Angiographic sequence of umbilical 
vein system refilling revealed signs of portal hypertension; hepatic veins were normal; 
hepatic artery was stretched with a filiform calibre (1 mm). Esophagogastroscopy showed 
an esophageal varicose vein (type 1, grade 1-2), without red spots; erosive not congestive 
antral gastropathy was diagnosed.  
A liver biopsy was obtained and, because of the low platelet count, a laparoscopic 
procedure was preferred to control eventual bleeding. Laparoscopy showed macronodules 
on the liver surface. The two surgical liver biopsy specimens showed irregular and 
confluent white areas with multinodular pattern, without fibrotic or cirrhotic aspect. 
Histological evaluation showed diagnostic features of NRHL. There were no histological 
features of cholangitis.  
Given the biochemical evidence of cholestasis, UDCA was administered at a dosage of 
10 mg/kg/day that was progressively increased to 20 mg/kg/day (1800 mg/day). First 
GGT and then AST and ALT normalized after a few months of treatment and remained 
normal in the following months (Figure 1a). Platelet count slightly increased on therapy 
(Figure 1b), while white blood cells remained unchanged (Figure 1c). 
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After 15 months of UDCA therapy, the esophageal varicose vein was not evident on 
esophagogastroscopy. Ultrasound confirmed the enlarged liver with a homogeneous 
echopattern and a hypoechoic lesion. The latter was studied with ultrasound contrast 
medium, which showed a non-enhancing nodule on arterial-phase and signal 
enhancement similar to the surrounding parenchyma on late-phase imaging. At 
ultrasonographic pulsed Doppler, P was 16 mm and PVmean was regular (24 cm/sec). 
The portal CI was reduced to 0.084 cm2/[cm/sec]. The magnetic resonance pattern, 
angiographic sequence and spleen size were unchanged. 
The patient after 30 months of therapy, during the summer holidays,  arbitrarily 
suspended UDCA treatment and a rapid increase in transaminases was observed 1 month 
after suspension. The prompt reinstitution of UDCA was followed by sustained 
normalization of liver enzyme (Fig. 1a). No drug other than UDCA was given throughout 
the entire observation period. This was documented by detailed interviews  performed at 
each visit. In this way, a close chronological relationship between the short period of 
UDCA withdrawal and the transient liver enzymes flare was observed.  
No systemic disease linked to NRHL was identified in our patient. Serum homocysteine, 
plasma factor II, V, IX and X activities, plasma protein C, protein S, and antithrombin III 
levels, lupus anticoagulant, anticardiolipin antibodies, anti-nuclear antibodies, serum 
complement levels, cytoplasmic-staining anti-neutrophil cytoplasmic antibodies, and 
perinuclear-staining antineutrophil cytoplasmic antibodies were within normal limits. 
 
Discussion. 
The clinical course of patients with NRHL is very variable and tends to be more severe in 
subjects presenting with haematemesis due to esophageal variceal bleeding. Since the 
natural history of NRHL is not well defined, management of patients is directed at 
treating the underlying disorder, if identified, and treating the complications of portal 
hypertension.1  
To the best of our knowledge, this is the first case of a patient with primary NRHL 
associated to portal hypertension in whom UDCA therapy was followed by a prompt 
reduction and sustained normalization of liver enzymes and no progression of portal 
hypertension throughout the follow-up.  
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Although the observation period was short to draw definitive conclusions about the 
therapeutic effect of UDCA administration on portal hypertension, it is to note that before 
the administration of UDCA, laboratory and sonographic signs of portal hypertension 
progressively worsened, whereas these parameters tended to improve during UDCA 
therapy. Previously, few cases of NRHL treated with UDCA7,8 have been reported but 
the impact of the drug on portal hypertension progression has never been documented.  
UDCA is a hydrophilic, tertiary bile acid widely used to treat patients with chronic 
cholestatic liver diseases. Given its cytoprotective, anti-apoptotic, anti-oxidative, 
choleretic, immunomodulatory and altering cell signaling properties, UDCA may affect 
various pathogenetic mechanisms involved in NRHL.9 UDCA prevents apoptosis in 
preclinical models of human diseases by inhibiting the mitochondrial pathway and 
disrupting the apoptotic cascade.10 It is conceivable that in NRHL an apoptotic 
mechanism, induced by ischemic injury, determines atrophy in the central areas (zone 
III), which are more vulnerable to ischemia. Central atrophy, in turn, leads to 
proliferation of neighbouring hepatocytes, which form regenerative nodules.1 These 
nodules compress intrahepatic portal radicles and intraparenchymal venules and/or 
sinusoids and promote portal hypertension. Moreover, as suggested by Wanless et al, 
structural obstruction of the portal venules due to recurrent embolization of the portal 
vein radicles by platelet aggregates as well as by larger thrombi generated in the portal 
venous system contribute to the progression of portal hypertension.2 UDCA therapy in 
patients affected by NRHL could disrupt key signalling pathways involved in apoptotic 
and necrotic cell death and so prevent hepatocyte proliferation and indirectly impede the 
development of portal hypertension. It is noteworthy that UDCA reduce the portohepatic 
gradient in rats with portal hypertension associated with biliary cirrhosis thereby 
suppressing hepatic thrombaxane A2 production and lipid peroxidation, and increasing 
the antioxidative defence mechanism.11 UDCA may prevent the development of portal 
hypertension also by improving endothelial function.12 In fact, in human vascular 
endothelial cells, bile acids increase nitric oxide production by increasing the intracellular 
concentration of Ca2+, and inhibit production of endothelin-1. The latter is directly 
involved in increasing intrahepatic vascular resistance in patients with hepatobiliary 
diseases.  
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Huet et al. recently reported worsening of portal hypertension in patients with primary 
biliary cirrhosis not treated with UDCA, and stabilization or improvement of portal 
hypertension in an encouraging percentage of UDCA-treated patients.13 Huet and 
colleagues monitored portal hypertension using the portohepatic gradient, whereas we 
used laboratory and sonographic indices and the esophagogastroscopy pattern. 13 
On the basis of our experience, UDCA administration could be considered as specific 
therapy for primary NRHL. Furthermore, it would be interesting to evaluate the role of 
UDCA in larger series of patients affected by NRHL and to analyze the potential  impact 
of treatment on the natural history of disease and prevention of  its complications.  Lastly, 
because UDCA is effective in the prevention of drug-induced hepatotoxicity,10 studies 
should be conducted to evaluate the effect of UDCA in NRHL induced by chronic 
treatment with drugs such as azathioprine or 6-thioguanine.  
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Figure 1A. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) profiles after 
ursodeoxycholic acid (UDCA) treatment. (b) Platelet count and white blood cells (c) profiles over time.  
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Figure 1B. Platelet count profiles over time.  
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Figure 1C. White blood cells count profile over time. 
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